Mutant TNFalpha negatively regulates human breast cancer stem cells from MCF7 in vitro.

abstract：:The hypothesis of the "liquid biopsy" using circulating tumor cells (CTCs) emerged as a minimally invasive alternative to traditional tissue biopsy to determine cancer therapy. Discordance for biomarkers expression between primary tumor tissue and circulating tumor cells (CTCs) has been widely reported, thus rendering...

journal_title：Cancer biology & therapy

authors： Raimondi C,Nicolazzo C,Gradilone A,Giannini G,De Falco E,Chimenti I,Varriale E,Hauch S,Plappert L,Cortesi E,Gazzaniga P

更新日期：2014-05-01 00:00:00

abstract：:Long standing chronic pancreatitis is a risk factor for developing pancreatic cancer. Inheritance of polymorphisms in SPINK1 and CFTR are associated with an increased risk of developing pancreatitis. The aim of this study was to determine if patients who carry polymorphisms in SPINK1 and CFTR are at increased risk of ...

journal_title：Cancer biology & therapy

authors： Matsubayashi H,Fukushima N,Sato N,Brune K,Canto M,Yeo CJ,Hruban RH,Kern SE,Goggins M

更新日期：2003-11-01 00:00:00

abstract：:Any drug selects for drug resistance. But super-antagonistic drug combinations can select for drug sensitivity. This has important application not only for antibacterial therapy but also for cancer therapy: to control cancer with lesser side effects and to eliminate drug-resistant cancer cells, while sparing sensitive...

journal_title：Cancer biology & therapy

authors： Blagosklonny MV

更新日期：2007-07-01 00:00:00

abstract：:One of the most active fields in cancer immunotherapy is the study of bispecific antibodies, which engage immune cells to kill cancer cells. However, a variety of issues are associated with most of current bispecific antibody formats. In this study, we present a novel bispecific antibody, BiSS (Bispecific antibody wit...

journal_title：Cancer biology & therapy

authors： Dong B,Zhou C,He P,Li J,Chen S,Miao J,Li Q,Wang Z

更新日期：2016-04-02 00:00:00

abstract：:Although most researchers in biology tend to focus on very specific issues and questions about their preferred gene or pathway, sometimes we face situations in which nature presents us with a remarkable example of a gene with multiple functions. Since the discovery of the early growth response 1 (EGR1) gene in the mid...

journal_title：Cancer biology & therapy

authors： DeLigio JT,Zorio DA

更新日期：2009-10-01 00:00:00

abstract：:The Bin1/Amphiphysin2 gene encodes several alternately spliced BAR adapter proteins that have been implicated in membrane-associated and nuclear processes. Bin1 expression is often attenuated during tumor progression and Bin1 splice isoforms that localize to the nucleus display tumor suppressor properties. While these...

journal_title：Cancer biology & therapy

authors： Muller AJ,DuHadaway JB,Donover PS,Sutanto-Ward E,Prendergast GC

更新日期：2004-12-01 00:00:00

abstract：:Expression of the heparanase gene is associated with invasive, angiogenic and metastatic potential of diverse malignant tumors and cell lines. Here we used RNA interference strategies to evaluate the role of human heparanase in breast malignancy and to explore the therapeutic potential of its specific targeting. The s...

journal_title：Cancer biology & therapy

authors： Zhang ZH,Chen Y,Zhao HJ,Xie CY,Ding J,Hou YT

更新日期：2007-04-01 00:00:00

abstract：:The small GTPase Rac1 regulates many cellular processes, including cytoskeletal reorganization, cell migration, proliferation, and survival. Additionally, Rac1 plays a major role in activating NF-κB-mediated transcription. Both Rac1 and NF-κB regulate many properties of the malignant phenotype, including anchorage-ind...

journal_title：Cancer biology & therapy

authors： Gastonguay A,Berg T,Hauser AD,Schuld N,Lorimer E,Williams CL

更新日期：2012-06-01 00:00:00

abstract：:Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that has mainly been studied in haematopoietic cells. We have investigated whether BTK is a potential therapeutic target in prostate cancer. We find that BTK is expressed in prostate cells, with the alternate BTK-C isoform predominantly expressed in pros...

journal_title：Cancer biology & therapy

authors： Kokabee L,Wang X,Sevinsky CJ,Wang WL,Cheu L,Chittur SV,Karimipoor M,Tenniswood M,Conklin DS

更新日期：2015-01-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) progresses from a chronic phase to a deadly blast crisis phase. While it is known that BCR-ABL initiates the disease and that secondary molecular and genetic abnormalities likely contribute to progression of the disease to blast crisis, details regarding the mechanism(s) of blast phase p...

journal_title：Cancer biology & therapy

authors： Griner LN,Reuther GW

更新日期：2010-11-15 00:00:00

abstract：:This study investigated different methods of EGFR (Epithelial Growth Factor Receptor) targeting in feline squamous cell carcinoma with the ultimate aim of establishing a large animal model of human head and neck cancer. Both small molecule receptor tyrosine kinase inhibitor (TKI) and RNA interference (RNAi) techniques...

journal_title：Cancer biology & therapy

authors： Bergkvist GT,Argyle DJ,Pang LY,Muirhead R,Yool DA

更新日期：2011-06-01 00:00:00

abstract：:Adult brain tumors establish an immunosuppressive tumor microenvironment as a modality of immune escape, with several immunotherapies designed to overcome this barrier. However, the relationship between tumor cells and immune cells in pediatric brain tumor patients is not as well-defined. In this study, we sought to d...

journal_title：Cancer biology & therapy

authors： Haberthur K,Brennan K,Hoglund V,Balcaitis S,Chinn H,Davis A,Kreuser S,Winter C,Leary SE,Deutsch GH,Ellenbogen RG,Crane CA

更新日期：2016-12-01 00:00:00

abstract：:A number of discoveries have clarified the molecular mechanism of apoptosis, thus clarifying the link between apoptosis and therapeutic outcome. Even though apoptosis is thought to play a major role in anticancer therapy, the clinical relevance of induction of apoptosis remains uncertain, particularly in solid tumors....

journal_title：Cancer biology & therapy

authors： Kim R,Emi M,Tanabe K

更新日期：2006-11-01 00:00:00

abstract：:Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non-small-cell lung cancer (NSCLC). Interestingly, treatment with these small molecule, reversible EGFR-TKIs leads to more positive respo...

journal_title：Cancer biology & therapy

authors： Xu Y,Liu H,Chen J,Zhou Q

更新日期：2010-04-15 00:00:00

abstract：PURPOSE:The sensitivity of lung cancer to gefitinib has been found to be associated with mutations at the tyrosine kinase domain of epidermal growth factor receptor (EGFR), yet similar observations are not available in other solid tumors. We recently identified mutations in the EGFR kinase domain in primary esophageal ...

journal_title：Cancer biology & therapy

authors： Guo M,Liu S,Herman JG,Zhuang H,Lu F

更新日期：2006-02-01 00:00:00

abstract：:Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refractory pancreatic canc...

journal_title：Cancer biology & therapy

authors： Samulitis BK,Pond KW,Pond E,Cress AE,Patel H,Wisner L,Patel C,Dorr RT,Landowski TH

更新日期：2015-01-01 00:00:00

abstract：:Li-Fraumeni syndrome (LFS) is primarily characterized by development of tumors exhibiting germ-line mutations in the p53 gene. Cell lines developed from patients of a LFS family have decreased p53 activity as evidenced by the absence of apoptosis upon etoposide treatment. To test our hypothesis that changes in gene ex...

journal_title：Cancer biology & therapy

authors： Sherif ZA,Sultan AS

更新日期：2013-01-01 00:00:00

abstract：:Hypoxia is known to play important role in cancer biology.  In sarcomas, hypoxia-induced protein biomarkers such as Hypoxia Inducible Factor-1a (HIF-1a), vascular endothelial growth factor (VEGF), and Erythropoietin (Epo) have been previously reported in only a few studies.  Moreover, the biologic significance and rel...

journal_title：Cancer biology & therapy

authors： Huang JH,Lee FS,Pasha TL,Sammel MD,Karakousis G,Xu G,Fraker D,Zhang PJ

更新日期：2010-02-01 00:00:00

abstract：:SUMO (small ubiquitin-related modifier) represents a class of ubiquitin-like proteins that is conjugated, like ubiquitin, by a set of enzymes to cellular regulatory proteins, including oncogenes and tumor suppressor genes, that play key roles in the control of cell growth, differentiation and apoptosis. SUMO conjugati...

journal_title：Cancer biology & therapy

authors： Alarcon-Vargas D,Ronai Z

更新日期：2002-05-01 00:00:00

abstract：:Dendritic cells (DC) operate through an immature (iDC) step (where tumor antigens are internalized) and a mature step (mDC) (where tumor antigens (TA) are cross-presented to naive TA-specific cytotoxic T lymphocyte (CTL) progenitors). Receptors by which cellbound antigens can access the DC cross-presentation pathway i...

journal_title：Cancer biology & therapy

authors： Signorino E,Brusa D,Granata R,Malavasi F,Ferrone S,Matera L

更新日期：2007-12-01 00:00:00

abstract：BACKGROUND:Unlike papillary thyroid cancer (PTC), anaplastic thyroid carcinoma (ATC) is extremely aggressive and rapidly lethal without effective therapies. However, the differences of master regulators and regulatory networks between PTC and ATC remain unclear. Methods: Three representative datasets comprising 32 ATC,...

journal_title：Cancer biology & therapy

authors： Pan Z,Li L,Qian Y,Ge X,Hu X,Zhang Y,Ge M,Huang P

更新日期：2020-09-01 00:00:00

abstract：:Progression of prostate cancer has been associated with EGFR and HER2 activation and to tumor-initiating cells contribution toward chemotherapy resistance. We investigated the efficacy of a dual intervention against EGFR and HER2 to deplete the tumor-initiating cells, optimize the chemotherapy management and prevent t...

journal_title：Cancer biology & therapy

authors： Rossini A,Giussani M,Ripamonti F,Aiello P,Regondi V,Balsari A,Triulzi T,Tagliabue E

更新日期：2020-05-03 00:00:00

abstract：:Drug resistance has always been the main problem in osteosarcoma treatment, and hypoxia seems to be one of the many causes for drug resistance. Therefore, in this study, we investigated how hypoxia triggers chemotherapy resistance in osteosarcoma. We first screened hypoxia- and normoxia- cultured osteosarcoma cells in...

journal_title：Cancer biology & therapy

authors： Ma Q,Zhang Y,Liu T,Jiang K,Wen Y,Fan Q,Qiu X

更新日期：2017-03-04 00:00:00

abstract：PURPOSE:Indoleamine 2,3-dioxygenase (IDO), a tryptophan catabolic enzyme, plays an important role in immune escape through suppressing T-cell function. Since Vav1 signaling pathway regulates T cell homeostasis, this study was designed to test the hypothesis that IDO induces T-cell immunosuppression through inhibiting V...

journal_title：Cancer biology & therapy

authors： Li R,Wei F,Yu J,Li H,Ren X,Hao X

更新日期：2009-07-01 00:00:00

abstract：:AMPK has been termed the fuel sensor of mammalian cells because it directly responds to the depletion of the fuel molecule ATP. In previous work, we found that AMPK is strongly activated by tumor-like hypoxia and glucose deprivation, independently of the oxygen response system associated with HIF-1. We also observed h...

journal_title：Cancer biology & therapy

authors： Laderoute KR,Calaoagan JM,Madrid PB,Klon AE,Ehrlich PJ

更新日期：2010-07-01 00:00:00

abstract：:Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims to elucidate this mechanism of c-Met TKI resistance by investigating key mTOR and Wnt signaling proteins in melanoma ce...

journal_title：Cancer biology & therapy

authors： Etnyre D,Stone AL,Fong JT,Jacobs RJ,Uppada SB,Botting GM,Rajanna S,Moravec DN,Shambannagari MR,Crees Z,Girard J,Bertram C,Puri N

更新日期：2014-09-01 00:00:00

abstract：:Chronic arsenic treatment induces epithelial-mesenchymal transition (EMT) and promotes tumorigenicity, but the mechanism is unclear. MiR-100 has been shown to be involved in this biologic process. In this study, we hypothesize that inactivation of miR-100 combined with low concentration of arsenic exposure could promo...

journal_title：Cancer biology & therapy

authors： Yang J,Chen Z,Wang X,Xu M,Fang H,Li F,Liu Y,Jiang Y,Ding Y,Li J,Wang S

更新日期：2017-12-02 00:00:00

abstract：:Methylation induces epigenetic silencing of tumor suppressor genes in human lung cancer. Inhibition of DNA methyltransferases by decitabine (DAC) can demethylate and activate epigenetically silenced tumor suppressor genes. Epigenetic therapy using DAC should be an attractive strategy for lung cancer therapy. FBW7 is a...

journal_title：Cancer biology & therapy

authors： Kim MJ,Chen G,Sica GL,Deng X

更新日期：2021-01-02 00:00:00

abstract：:Melanoma is the deadliest form of skin cancer. In the early stages, melanoma can be treated successfully with surgery alone and survival rates are high, but after metastasis survival rates drop significantly. Therefore, early and correct diagnosis is key for ensuring patients have the best possible prognosis. Melanoma...

journal_title：Cancer biology & therapy

authors： Davis LE,Shalin SC,Tackett AJ

更新日期：2019-01-01 00:00:00

abstract：:Obesity is considered one of the risk factors for many cancers. Serum leptin levels are often elevated in obese people. Leptin has been reported to act as a mitogenic agent and promote renal cancer cell proliferation, whereas the detailed mechanisms still remain to be elucidated. The purpose of this study is to invest...

journal_title：Cancer biology & therapy

authors： Li L,Gao Y,Zhang LL,He DL

更新日期：2008-11-01 00:00:00